 placebo-control double-blind two-cent pilot trial cop chronic progress multipl sclerosi cop effect safe previou clinic trial current trial chronic-progress patient major end point progress unit baselin disabl kurtzk expand disabl statu scale control patient differ overal surviv curv signific progress rate month placebo group probabl progress cop placebo signific differ month placebo cop center two-year progress rate secondari end point unconfirm progress progress edss unit signific